Related Experiment Video
Updated: Feb 27, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Drug-Resistant tuberculosis - primary transmission and management
Alexander C Outhred1, Philip N Britton1, Ben J Marais1
1The Children's Hospital at Westmead and the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia.
Drug-resistant tuberculosis (TB) is spreading globally, despite control efforts. Enhanced infection control and improved access to treatment are crucial, especially for vulnerable children in endemic areas.
Area of Science:
- * Infectious Diseases
- * Public Health
- * Genomics
Background:
- * The Directly Observed Treatment Short-course (DOTS) strategy has been instrumental in global tuberculosis (TB) control.
- * However, DOTS has been insufficient in preventing the emergence and spread of drug-resistant TB strains.
- * Genomic data reveal widespread transmission of drug-resistant Mycobacterium tuberculosis, indicating epidemic potential.
Purpose of the Study:
- * To review new insights into the transmission dynamics of drug-resistant TB.
- * To estimate the disease burden of drug-resistant TB in children.
- * To discuss optimal management strategies for drug-resistant TB, particularly in vulnerable populations.
Main Methods:
- * Review of genomic evidence on Mycobacterium tuberculosis transmission.
- * Analysis of disease burden in children affected by drug-resistant TB.
- * Synthesis of current knowledge on management and control strategies.
Main Results:
- * Genomic studies confirm the transmission of drug-resistant TB strains across diverse settings.
- * Young children in TB-endemic regions are identified as a particularly vulnerable group.
- * There is an urgent need for advances in TB drug and vaccine development.
Conclusions:
- * Enhanced infection control measures are essential in healthcare and congregate settings to curb TB spread.
- * Improving access to existing preventive therapies and treatments for drug-resistant TB can reduce disease burden and negative outcomes in children.
- * Integrated strategies addressing transmission, burden, and management are critical for combating drug-resistant TB.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

